Search results for "Zole"

showing 10 items of 2482 documents

Synthesis of alkyl-5,8-dimethyl-6-phenyl-5,6-dihydropyrazolo[3,4-f] [1,2,3,5]tetrazepin-4(3H)-ones of pharmaceutical interest

2006

The multistep synthesis of two pyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one derivatives, a new class of fused 1,2,3,5-tetrazepinones with potential antiproliferative activity, has been carried out. Owing to the instability of the above compounds, the last step of the synthesis was performed at -5/0 degrees C. The obtained tetrazepinones, when allowed to stand at r.t. for 24 h, afforded quantitatively 1-phenyl-3,6-dimethylpyrazolo [3,4-d][1,2,3] triazole.

lcsh:QD241-441chemistry.chemical_classificationchemistry.chemical_compoundlcsh:Organic chemistryChemistryOrganic ChemistryTriazole1235-tetrazepinones pyrazoles pyrazolo[34-f][1235]-tetrazepinones drug resistance antiproliferative activityCombinatorial chemistryAlkyl
researchProduct

Synthesis of pyrazolo[4,3-c][1,2,6]benzothiadiazocine, a new ring system as potential COX inhibitor

2012

Derivatives of the new ring system 1,4-dihydropyrazolo[4,3-c][1,2,6] benzothiadiazocin-11(10H)one 5,5-dioxide were synthesized in five or six steps in 57-66% overall yields and tested as COX inhibitors.

lcsh:QD241-441chemistry.chemical_compoundCOX Inhibitorlcsh:Organic chemistryChemistryStereochemistry[126]Benzothiadiazocine 14-dihydropyrazolo[43-c][126benzothiadiazocin-11(10H)one 55-dioxides pyrazole COX inhibitorsOrganic ChemistryPyrazoleRing (chemistry)Settore CHIM/08 - Chimica FarmaceuticaARKIVOC
researchProduct

SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF 7-SUBSTITUTED1-ETHYL-3,4,10-TRIMETHYL-1,10-DIHYDRO-11H-PYRAZOLO(3,4-c)(1,6)BENZODIAZOCIN-11-ONE: A NEW RI…

2004

Derivatives of the title ring system of type 10 were obtained in good yield by fusion of the intermediates 12. Attempt to cyclize the acetylamino derivative 9 under Bischler-Napieralski conditions failed because of the insufficient electronic density in the position 4 of the pyrazole ring created by the adjacent carbonyl moiety. The derivatives of the new ring system, assayed as anxiolytic agents, showed no significant activity.

lcsh:QD241-441chemistry.chemical_compoundlcsh:Organic chemistryChemistryStereochemistryYield (chemistry)Organic ChemistryMoietyPyrazoleRing (chemistry)Anxiolytic agents
researchProduct

Synthesis of pyrazole-4-carbohydrazide derivatives of pharmaceutical interest

2003

New 1-phenylor 1-methyl-5-benzamidopyrazole-4-carbohydrazide derivatives were prepared in 70–90% yields from 1-methylor 1-phenyl-6-phenylpyrazolo[3,4-d]1,3-oxazin-4(1H)-one derivatives and hydrazine hydrate. Small quantities of the isomeric 5-aminopyrazole-4-(Nbenzoyl)hydrazides were detected in some reaction mixtures, proving that intramolecular benzoyl migration can take place in the 5-benzamidopyrazole-4-carbohydrazide molecule. The direct formation of pyrazole-4-carbohydrazides from 5-benzamidopyrazole-4-carboxylic acid ethyl esters and hydrazine hydrate was unsuccessful.

lcsh:QD241-441chemistry.chemical_compoundlcsh:Organic chemistrychemistryIntramolecular forceOrganic ChemistryHydrazineMoleculePyrazoleCarbohydrazideEthyl esterHydrateMedicinal chemistryArkivoc
researchProduct

Palladium-Catalyzed Direct Arylation of Heteroaromatics with Activated Aryl Chlorides Using a Sterically Relieved Ferrocenyl-Diphosphane

2012

International audience; The palladium-catalyzed direct arylations at C3 or C4 positions of heteroaromatics are known to be more challenging than at C2 or C5 positions. Aryl chlorides are also challenging substrates for direct arylation of heteroaromatics. We observed that in the presence of a palladium-catalyst combining only 0.5 mol % of Pd(OAc)2 with the sterically relieved new ferrocenyl diphosphane Sylphos, the direct arylation at C3 or C4 of oxazoles, a benzofuran, an indole, and a pyrazole was found to proceed in moderate to high yields using a variety of electron deficient aryl chlorides. Turnover numbers up to 176 have been obtained with this catalyst. Assessment of the electron-don…

ligand designSteric effectsC−H bond functionalizationaryl chlorideschemistry.chemical_elementPyrazole010402 general chemistry01 natural sciencesMedicinal chemistryCatalysis[ CHIM.CATA ] Chemical Sciences/Catalysischemistry.chemical_compoundOrganic chemistryDiphosphaneMethyleneBenzofuranIndole test010405 organic chemistryArylferrocenylphosphaneheteroarenes[CHIM.CATA]Chemical Sciences/CatalysisGeneral Chemistrypalladium0104 chemical scienceschemistry13. Climate actionPalladiumACS Catalysis
researchProduct

Mutant HRAS as novel target for MEK and mTOR inhibitors.

2015

HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS as drug target has not been investigated so far. Here, we show that mutant HRAS hyperactivates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophageal cancer. HRAS mutation sensitized toward growth inhibition by the MEK inhibitors AZD6244, MEK162 and PD0325901. Further, we found that MEK inhibitors induce apoptosis in mutant HRAS cell lines but not in cell lines lacking RAS mutations. In addition, knockdown of HRAS by siRNA blocked cell growth in mutant HRAS cell lines. Inhibition of the PI3K pathway alone or in combination with MEK inhibitors did not alter signaling nor had an imp…

mTOR inhibitorMutantBlotting Western610 Medicine & healthApoptosisMice SCIDCell LineProto-Oncogene Proteins p21(ras)chemistry.chemical_compoundCell Line TumorNeoplasmsMedicineAnimalsHumansHRASHRAS mutationsProtein Kinase InhibitorsPI3K/AKT/mTOR pathwayCell ProliferationGeneticsMitogen-Activated Protein Kinase KinasesMEK inhibitorOncogeneCell growthbusiness.industryMEK inhibitorTOR Serine-Threonine KinasesDiphenylamineXenograft Model Antitumor AssaysTumor Burdenlung cancer10219 Clinic for Gastroenterology and HepatologyCell Transformation NeoplasticOncologychemistry10032 Clinic for Oncology and HematologyBenzamidesMutationCancer researchbladder cancer2730 OncologyBenzimidazolesRNA InterferenceSignal transductionGrowth inhibitionbusinessSignal TransductionResearch PaperOncotarget
researchProduct

Determination of Drug Concentrations in Serum and Dopamine Receptor Occupancy in Brain for Optimal Antipsychotic Drug Therapy

2009

Evidence has been given that antipsychotic effects of dopamine receptor antagonists are associated with 60 and 80% striatal dopamine D2 and D3 receptor occupancy. Receptor occupancy correlates well with concentrations of the antipsychotic drugs in serum or plasma, much better than the dose. The latter is consistent with weak correlations between antipsychotic dose and serum concentrations and explained by the high interindividual variabilities in drug metabolism. Using positron emission tomography (PET) for in vivo determination of dopamine receptor occupancy in conjunction with drug concentration measurements “therapeutic windows” could be calculated for the atypical antipsychotic drugs am…

medicine.diagnostic_testbusiness.industrymedicine.drug_classAtypical antipsychoticPharmacologyPsychiatry and Mental healthDopamine receptorDopamine receptor D3Therapeutic drug monitoringAnesthesiaMedicineZiprasidoneAripiprazoleAmisulpridebusinessClozapinemedicine.drugEuropean Psychiatry
researchProduct

Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors

2020

[Image: see text] Breast cancer (BC) is the most diffused cancer type in women and the second leading cause of death among the female population. Effective strategies to fight estrogen responsive (ER+) BC, which represents 70% of all BC cases, rely on estrogen deprivation, via the inhibition of the aromatase enzyme, or the modulation of its cognate estrogen receptor. Current clinical therapies significantly increased patient survival time. Nevertheless, the onset of resistance in metastatic BC patients undergoing prolonged treatments is becoming a current clinical challenge, urgently demanding to devise innovative strategies. In this context, here we designed, synthesized, and performed in …

medicine.drug_classAllosteric regulation01 natural sciencesBiochemistryBreast cancerbreast cancerDrug Discoverymedicinecytochromes P450AromataseCause of deathFemale populationchemistry.chemical_classificationbiology010405 organic chemistrybusiness.industrymolecular dynamicOrganic ChemistryDual modeAromatase inhibitormedicine.diseasemolecular dynamics0104 chemical sciences010404 medicinal & biomolecular chemistryAromatase inhibitorschemistryEstrogenSettore CHIM/03 - Chimica Generale E Inorganicaxanthonebiology.proteinCancer researchAzolebusiness
researchProduct

Treatment of pulmonary embolism.

2015

International audience; The treatment of pulmonary embolism is going to be deeply modified by the development of Direct Oral Anticoagulants (DOACs). There are currently three anti-Xa factors (rivaroxaban, apixaban, edoxaban) and one anti-IIa factor (dabigatran) labeled by the FDA and the EMA. All these drugs are direct anticoagulant, orally effective, without the need for adaptation to hemostasis test. As kidney excretion is involved for all of them, they are contra-indicated in patients with severe renal failure (creatinine clearance<30mL/min according to Cockcroft & Gault formula). All the anti-Xa factor drugs are metabolized by liver cytochromes and then contra-indicated in case of liver…

medicine.drug_classPyridinesPyridones[SDV]Life Sciences [q-bio]PopulationRenal functionRisk AssessmentAntithrombinsDabigatranchemistry.chemical_compoundRivaroxaban[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemEdoxaban[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineHumanseducationeducation.field_of_studyRivaroxabanClinical Trials as Topic[ SDV ] Life Sciences [q-bio]business.industryMedicine (all)AnticoagulantGeneral MedicineVenous Thromboembolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthPulmonary embolismDabigatranThiazolesAntithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Medicine (all)chemistryAnesthesiaPyrazolesApixabanbusinessPulmonary Embolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drugFactor Xa Inhibitors
researchProduct

Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib

2019

Despite the huge success of tyrosine kinase inhibitors as anticancer agents, severe side effects are a major problem. In order to overcome this drawback, the first hypoxia-activatable 2-nitroimidazole-based prodrugs of the clinically approved ALK and c-MET inhibitor crizotinib were developed. The 2-aminopyridine functionality of crizotinib (essential for target kinase binding) was considered as ideal position for prodrug derivatization. Consequently, two different prodrugs were synthesized with the nitroimidazole unit attached to crizotinib either via carbamoylation (A) or alkylation (B) of the 2-aminopyridine moiety. The successful prodrug design could be proven by docking studies and a dr…

medicine.drug_classTyrosine kinase inhibitorAntineoplastic Agents01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitorStructure-Activity Relationshipchemistry.chemical_compoundDrug DevelopmentCrizotinibIn vivoDrug DiscoverymedicineHumansAnaplastic Lymphoma KinaseProdrugsHypoxiaProdrugProtein Kinase InhibitorsMolecular BiologyCells CulturedCell ProliferationNitroimidazoleDose-Response Relationship DrugMolecular StructureCrizotinib010405 organic chemistryChemistryNitroimidazoleOrganic ChemistryProto-Oncogene Proteins c-metProdrugCell Hypoxia0104 chemical sciences010404 medicinal & biomolecular chemistrySettore CHIM/03 - Chimica Generale E InorganicaDocking (molecular)Cancer researchDrug Screening Assays AntitumorKinase bindingTyrosine kinasemedicine.drugBioorganic Chemistry
researchProduct